Compare Abeona Therapeutics Inc (ABEO) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lumen Technologies Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Lumen Technologies Inc trades at $6.47 (market cap $6.64B). The key difference: Lumen Technologies Inc is far larger — about 17.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | LUMN | |
|---|---|---|
Market Cap | $373.32M | $6.64B |
Sector | Health | Media |
52-Week High | $7.23 | $11.83 |
52-Week Low | $4.17 | $3.70 |
Enterprise Value | $228.22M | $18.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
LUMN trades at $6.44, up 0.16% on the day, with a bearish technical signal but bullish oscillators. The company reported a net loss of $1.74B in 2025, though it beat EPS estimates in two of the last three quarters. Recent news highlights the completion of the Alkira acquisition, aimed at boosting its AI-era networking capabilities. Revenue has declined from $17.5B in 2022 to $12.4B in 2025, with a negative net income margin of -14.34%.
The outlook remains challenging due to persistent losses and high debt, but strategic acquisitions and a 15% forward free cash flow yield offer potential upside. Risks include execution hurdles in integrating acquisitions and intense telecom competition. Analyst consensus is a Hold with a $8.25 price target, suggesting cautious optimism amid fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
